Ordering
Available Variants5 mg
CHA.48652-5mg
Price
€110.40
Available – Dispatch in 14 days
25 mg
CHA.48652-25mg
Price
€364.00
Available – Dispatch in 14 days
4 g
CHA.48652-4g
Price
€68.24
Available – Dispatch in 14 days
20 g
CHA.48652-20g
Price
€132.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.48652-5mg | €110.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.48652-25mg | €364.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
4 g | CHA.48652-4g | €68.24 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
20 g | CHA.48652-20g | €132.00 |
≥98% (HPLC), farnesyl transferase inhibitor, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C27H31Br2ClN4O2 |
|---|---|
| CAS Number | 193275-84-2 |
| Molecular Weight | 638.82 |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 329825894 |
| NACRES | NA.77 |
| MDL number | MFCD06795138 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H315,H319,H335 |
| pcodes | P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338 |
| Hazard Classifications | Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 |
| target_organs | Respiratory system |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Lonafarnib, with a CAS number of 193275-84-2, not 7440-22-4, is a synthetic inhibitor of farnesyltransferase, an enzyme involved in the post-translational modification of proteins. It has been investigated as a potential therapeutic agent for the treatment of various cancers, including hepatocellular carcinoma and solid tumors. Lonafarnib works by blocking the farnesylation of Ras proteins, which are often mutated and oncogenic in cancer cells, thereby inhibiting their ability to promote cell growth and proliferation. In clinical trials, lonafarnib has shown promise as a single agent and in combination with other therapies, demonstrating anti-tumor activity and a manageable safety profile. Further research is needed to fully explore its potential as a cancer treatment and to optimize its use in combination with other therapies to improve patient outcomes. The correct CAS number for lonafarnib should be used for accurate identification.
